PharmaCyte Biotech, Inc. PMCB
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.11M | 4.91M | 4.93M | 3.75M | 3.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.46M | 5.30M | 5.38M | 4.23M | 3.96M |
| Operating Income | -5.46M | -5.30M | -5.38M | -4.23M | -3.96M |
| Income Before Tax | -16.15M | -19.42M | -3.28M | -7.07M | -1.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.15 | -19.42 | -3.28 | -7.07 | -1.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.15M | -19.42M | -3.28M | -7.07M | -1.13M |
| EBIT | -5.46M | -5.30M | -5.38M | -4.23M | -3.96M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.40 | -3.09 | -1.05 | -1.32 | -0.30 |
| Normalized Basic EPS | -0.58 | -1.12 | -0.56 | -0.51 | -0.04 |
| EPS Diluted | -2.40 | -3.09 | -1.05 | -1.32 | -0.30 |
| Normalized Diluted EPS | -0.58 | -1.12 | -0.56 | -0.51 | -0.04 |
| Average Basic Shares Outstanding | 37.45M | 33.51M | 29.71M | 27.41M | 28.25M |
| Average Diluted Shares Outstanding | 37.45M | 33.51M | 29.71M | 27.41M | 28.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -2.04% | -1.27% | -4.96% | -0.87% | -- |